1. Emerging CVOT Data and Clinical Application

3. 9 Years Since the FDA’s 2008 Guidance on CVOTs for T2D Drugs

4. 3 DPP-4 Inhibitors and 1 GLP-1 RA Were the First to Demonstrate CV Safety

5. Now 4 CVOTs Demonstrate CV Benefit

6. ORIGIN CVOT of Insulin Glargine

7. DEVOTE CVOT of Insulin Degludec

8. CANVAS Program Included CANVAS and CANVAS-R

9. Canagliflozin Lowered Risk for CV Death, Nonfatal MI, and Nonfatal Stroke

10. Is Canagliflozin Renoprotective?

11. EMPA-REG OUTCOME and CANVAS

12. Baseline Characteristics of Population in EMPA-REG OUTCOME

13. CANVAS Primary Prevention and Secondary Prevention and Effect on Stroke

14. EMPA-REG OUTCOME and CANVAS Heart Failure Hospitalization and Death From CV Causes

15. Putting Data Into Clinical Context

16. CVOTs Designed for Glycemic Equipoise

17. Exploring the Potential Renal Benefits of Canagliflozin

18. Ongoing Renal Outcome Studies

19. Higher Risk for Amputations in Patients Taking Canagliflozin

20. FDA Safety Alert May 16, 2017

21. Fracture Risk for Canagliflozin in CANVAS

22. Closing Comments

23. Abbreviations

24. Abbreviations (cont)